EFFECT OF PHARMACIST-LED ANTIMICROBIAL DOSE OPTIMIZATION IN ADULT INTENSIVE CARE UNITS: A SYSTEMATIC REVIEW WITH EXPLORATORY META-ANALYSIS OF DOSE ADJUSTMENT, THERAPEUTIC DRUG MONITORING, AND PHARMACOKINETIC-GUIDED DOSING
Keywords:
clinical pharmacist; intensive care; antimicrobial dosing; therapeutic drug monitoring; model-informed precision dosing; vancomycin; Saudi ArabiaAbstract
Background: Critical illness alters antimicrobial pharmacokinetics, and under- or over-dosing is common in intensive care units (ICUs). Clinical pharmacists can adjust doses, run therapeutic drug monitoring (TDM) and apply pharmacokinetic (PK) models, but the clinical effect of these activities in adult ICUs is unclear. Methods: We searched PubMed (last run 18 November 2026) following PRISMA 2020 for comparative studies of pharmacist-led or pharmacist-delivered antimicrobial dose optimization in adult ICUs. Outcomes were dosing appropriateness or PK/PD target attainment, mortality, length of stay, and vancomycin-associated acute kidney injury (AKI). Risk of bias was judged with ROBINS-I principles, and certainty with GRADE. Pooling was attempted only where at least two studies reported a comparable effect measure. Results: Of 108 unique records screened, 5 non-randomized studies were included (Thailand, China, Germany, Palestine, United States); no eligible Saudi or Gulf comparative study was found. Pharmacist-led programmes improved dosing appropriateness (36% to 63.6% of prescriptions in one study) and vancomycin target attainment (55.1% to 70.2%). ICU mortality fell from 29.4% to 18.6% in one Thai pre-post study but did not differ in the other studies reporting it. Mortality could not be pooled. For vancomycin AKI, AUC/Bayesian pharmacist-delivered dosing versus trough-guided dosing gave a pooled odds ratio of 0.72 (95% CI 0.58–0.89; two studies, I² = 0%), with one study carrying 96% of the weight. Certainty of evidence was very low for all outcomes. Conclusions: Pharmacist-led dose optimization reliably improves process measures, and may reduce vancomycin nephrotoxicity, but its effect on mortality is unproven. Controlled, ICU-specific studies, including studies from Saudi Arabia, are needed.

